Eli Lilly’s senior vice president and chief financial officer Josh Smiley announced plans for the Indianapolis-based pharmaceutical company to spend from $1 billion to $5 billion each quarter this year as it plans to bolster its pipeline. They’ve already gotten…
Novo Nordisk’s Ozempic Wins Approval for Reducing Cardiovascular Events in Diabetes Patients
Novo Nordisk’s Ozempic (semaglutide) won approval from the U.S. Food and Drug Administration (FDA) to reduce the risk of major adverse cardiovascular events (MACE) such as heart attack, stroke, or death in adults with type 2 diabetes and known heart…
Algernon Pharmaceuticals Appoints Novotech as CRO for First Phase 2 Trial and Announces Novotech’s $220K Equity Investment
VANCOUVER, British Columbia, Jan. 17, 2020 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that it has appointed Novotech as the contract…
Medtronic buys new spinal cord tech to boost pain therapies unit
Dive Brief: Medtronic announced late Wednesday it acquired Stimgenics, a Bloomington, Illinois-based startup that’s developed a novel spinal cord stimulation waveform Medtronic plans to deliver via its Intellis implantable neurostimulator to treat chronic pain. Medtronic expects the deal to be…
JenaValve TAVR tech amid wave to get breakthrough device status from FDA
Dive Brief: FDA has granted breakthrough device designation to a transcatheter aortic valve replacement system in development at JenaValve Technology, the company said Thursday. JenaValve is working to fill an unoccupied niche in the fast-growing TAVR market by winning approval…
Amid Q4 letdown, Boston Scientific targets $1B in structural heart, $2B single-use endoscope market
After reporting a fourth-quarter revenue shortfall due to a slowdown in its cardiac rhythm management division, Boston Scientific on Tuesday said it aims to deliver revenue growth above its medtech peer group over the next three years by reshaping its…
FDA OKs Abbott clinical trial of MitraClip in moderate risk patients
Dive Brief: Abbott announced Monday FDA approved a clinical trial the company hopes will lead to an expansion of MitraClip’s indication to include patients with moderate surgical risk. The transcatheter mitral valve repair device, used to treat primary mitral regurgitation…
Adaptimmune and Astellas to Co-Develop Allogenic CAR-T and TCR T-Cell Therapies
Shares of Adaptimmune have skyrocketed since the opening bell on Jan. 13. The stock closed up 200% Monday after the company announced positive results with its SPEAR-T cancer program and has continued to rise this morning after it struck a…
Gilead Backs Startup Kyverna Therapeutics with Financing, Collaborative Agreement
Gilead Sciences is boosting support for a Bay Area startup looking to develop a new class of therapies for autoimmune diseases. Gilead, along with two venture capital groups, provided Kyverna Therapeutics with an infusion of $25 million and also struck a…
MorphoSys gets $750m from Incyte for anti-CD19 cancer drug
Incyte has agreed a deal with Germany’s MorphoSys to license an antibody that could be an alternative to therapies for blood cancers sold by Amgen, Novartis and Gilead Sciences. Incyte is paying $750 million upfront for the antibody – called…
